Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
D000225:Adenine / Q000494:pharmacology; D000818:Animals; D001835:Body Weight; D003561:Cytarabine / Q000627:therapeutic use; D004336:Drug Antagonism; D004357:Drug Synergism; D005472:Fluorouracil / Q000627:therapeutic use; D006147:Guanine / Q000494:pharmacology; D007938:Leukemia / Q000188:drug therapy*; D007939:Leukemia L1210 / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D009705:Nucleosides / Q000627:therapeutic use*; D010770:Phosphotransferases / Q000378:metabolism; D011687:Purines / Q000494:pharmacology*; D014750:Vincristine / Q000627:therapeutic use
D009705:Nucleosides; D011687:Purines; D003561:Cytarabine; D014750:Vincristine; D006147:Guanine; D015122:Mercaptopurine; D010770:Phosphotransferases; D000225:Adenine; D005472:Fluorouracil; D008727:Methotrexate